本文選題：參斛復(fù)方　切入點(diǎn)：冠心病　出處：《中國(guó)中西醫(yī)結(jié)合雜志》2017年10期 　論文類型：期刊論文

【摘要】：目的觀察參斛復(fù)方不同劑型治療冠狀動(dòng)脈粥樣硬化性心臟病的臨床療效。方法將230例冠狀動(dòng)脈粥樣硬化性心臟病患者隨機(jī)分為3組:基礎(chǔ)治療組30例,試驗(yàn)組100例和對(duì)照組100例�；A(chǔ)治療組給予冠心病基礎(chǔ)治療,試驗(yàn)組予冠心病基礎(chǔ)治療+參斛復(fù)方中藥破壁飲片(3.5 g/袋,每次1袋,每日2次,開水沖服)治療,對(duì)照組給予冠心病基礎(chǔ)治療+參斛復(fù)方合劑(每次50 m L,每日2次),各組均持續(xù)治療6個(gè)月。檢測(cè)各組患者治療前后高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、總膽固醇(TG)、同型半胱氨酸(Hcy)、超敏C反應(yīng)蛋白(hs-CRP)、血栓素(TXA2)及前列環(huán)素(PGI2)水平。結(jié)果治療過(guò)程中脫落32例,最終完成198例。與本組治療前比較,治療后各組HDL、LDL、TG、Hcy及hs-CRP水平差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05),對(duì)照組和試驗(yàn)組TXA2水平及TXA2/PGI2比值均降低(P0.05);與基礎(chǔ)治療組同期比較,治療后對(duì)照組及試驗(yàn)組TXA2水平及TXA2/PGI2比值亦降低(P0.05)。結(jié)論參斛復(fù)方不同劑型在抗血小板聚集及改善微循環(huán)具有一定作用。
[Abstract]:Objective To observe the clinical efficacy of different dosage of Shenhu compound for the treatment of coronary atherosclerotic heart disease. Methods 230 cases of patients with coronary heart disease were randomly divided into 3 groups: 30 cases in the treatment group, 100 cases of test group and 100 cases in the control group. The treatment group was given basic treatment based crown heart disease, the test group received the basis of coronary heart disease compound Chinese medicine treatment + Shenhu broken pieces (3.5 g/ bag, 1 bag each time, 2 times daily, boiling water) treatment, the control group was given routine treatment plus coronary heart disease of Shenhu compound (L 50 m each time, 2 times daily), treatment groups were continued for 6 months. Before and after treatment in patients with high density detection lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol (TG), homocysteine (Hcy), high sensitive C reactive protein (hs-CRP), thromboxane (TXA2) and prostacyclin (PGI2) level. The results of 32 cases treated off process, completed in 198 cases. The treatment group Before treatment, after treatment of HDL, LDL, TG, Hcy and hs-CRP level differences were not statistically significant (P0.05), the control group and the experimental group TXA2 level and TXA2/PGI2 ratio were decreased (P0.05); compared with the basic treatment group, control group and experimental group after treatment, TXA2 level and TXA2/PGI2 ratio were decreased (P0.05). Conclusion: Dendrobium Compound with different formulations in platelet aggregation and improve microcirculation has a certain role.

【作者單位】： 廣州中醫(yī)藥大學(xué)附屬中山醫(yī)院綜合科;
【基金】：廣東省中醫(yī)藥管理局資助項(xiàng)目(No.20132112)
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 周長(zhǎng)文;沈顯群;賈駿;王懿釩;冷志宏;羅素新;;糖尿病合并冠心病老年患者氯吡格雷抵抗的危險(xiǎn)因素分析[J];檢驗(yàn)醫(yī)學(xué)與臨床;2014年10期

2 劉光全;付菊;;重慶市永川區(qū)老年冠心病合并糖尿病患者的高危因素分析及干預(yù)對(duì)策[J];檢驗(yàn)醫(yī)學(xué)與臨床;2014年10期

3 胡艷;肖踐明;;光學(xué)相干斷層成像技術(shù)在冠心病臨界病變中的應(yīng)用[J];臨床醫(yī)學(xué);2014年05期

相關(guān)博士學(xué)位論文 前1條

1 何晨;臨床因素和解剖因素聯(lián)合應(yīng)用對(duì)冠心病介入術(shù)后患者遠(yuǎn)期預(yù)后的預(yù)測(cè)價(jià)值[D];北京協(xié)和醫(yī)學(xué)院;2017年

，

本文編號(hào)：1613422